Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doxepin is a tricyclic antidepressant (TCA) used primarily to treat major depressive disorder, anxiety disorders, and insomnia. It is also sometimes used as an alternative treatment for chronic hives when other antihistamines are ineffective. Doxepin works mainly by inhibiting the reuptake of norepinephrine and serotonin in the brain, thereby increasing their levels and improving mood balance[1][2][4][8]. At lower doses (such as those used for insomnia), it acts predominantly as a highly selective antagonist of the histamine H1 receptor, which promotes sleep maintenance[6]. Doxepin also exhibits anticholinergic, antiadrenergic, antiserotonergic effects and can block voltage-gated sodium channels[7]. The drug was originally developed by Pfizer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxepin.